De novo design of PD-L1 protein-based inhibitor – UROP Spring Symposium 2021

De novo design of PD-L1 protein-based inhibitor

Christine Wu


Pronouns: she/her

Research Mentor(s): Jaie Woodard, Postdoctoral Fellow
Research Mentor School/College/Department: Computational Medicine and Bioinformatics, Michigan Medicine
Presentation Date: Thursday, April 22, 2021
Session: Session 5 (3pm-3:50pm)
Breakout Room: Room 11
Presenter: 3

Event Link


Certain types of proteins, such as PD-L1, enable a cancer cell to bypass T-cell immune checkpoints. This results in cancer cells being undetected in the body and time for cancer cells to grow and multiply. This investigation attempts to create a favorable PD-L1 protein inhibitor so that the cancer cells that it resides on will be detected by the body’s immune response. Through the usage of PERL programming, EvoDesign, and FoldDesign, the best protein inhibitor will be determined by its binding affinity to the protein and its stability and will be tested in a wet lab in the future. The results of this study will eventually be used and tested to see whether the designed inhibitor is suitable for usage.

Authors: Christine Wu, Robin Pearce, Yang Zhang
Research Method: Computer Programming

lsa logoum logo